Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX DS versus COXANTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX DS versus COXANTO.
ANAPROX DS vs COXANTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
550 mg orally every 8 to 12 hours; maximum 1375 mg/day.
1 g intravenous every 6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 12–17 hours (mean ~14 hours), allowing twice-daily dosing. Steady-state is achieved after 4–5 doses.
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
Renal elimination of naproxen and its metabolites accounts for approximately 95% of the dose, with about 60% as unchanged drug and 40% as conjugated or hydroxylated metabolites. Biliary/fecal excretion is negligible (<5%).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
NSAID
NSAID